US Earnings Financial Results SEC Filings — April 15, 2026

15-04-2026

Petros Pharmaceuticals reported a net income of $1,913,595 for the year ended December 31, 2025, swinging from a $14,318,790 loss in 2024, primarily due to a $6,973,302 gain from subsidiary assignment and Vivus settlement alongside a reduced discontinued operations loss of $559,665 versus $13,613,616. However, operating expenses remained flat at approximately $4.6 million with SG&A up slightly 0.3% YoY, resulting in a $4,641,350 operating loss, increased operating cash burn to $4,743,381 from $4,054,565, and substantial deemed dividends leading to a $50,102,850 net loss attributable to common stockholders. Cash and equivalents improved to $5,136,722 from $1,718,645, bolstered by $8,161,458 in financing activities, while total assets declined to $5,163,598 from $10,635,310 and stockholders' equity turned positive at $2,870,854 from a $7,467,578 deficit.

• ·Total other income declined to $141,308 in 2025 from $3,921,769 in 2024.
• ·Interest income decreased to $256,933 from $371,769 YoY.
• ·Warrant issuance costs of $10,420,982 in 2025.
• ·Change in fair value of warrant liability gain of $10,305,357 in 2025.
• ·Loss before income taxes widened to $(4,500,042) from $(705,174).
• ·Total liabilities dropped to $2,292,744 from $18,102,888.
• ·Accumulated deficit improved to $(111,294,776) from $(113,208,371).
• ·Preferred stock dividend and cash premiums $(973,984) in 2025 versus $(2,308,122) in 2024.
• ·Deemed dividend on Series A Preferred Warrants $(41,601,824) in 2025.

15-04-2026

Total revenue increased approximately 5% YoY to $41,441,030 in 2025 from $39,492,012, primarily driven by 5.6% growth in healthcare revenue to $41,375,235, though rental revenue fell to zero following the sale of Goodwill Hunting LLC. Operating expenses rose 1.9% to $43,005,701, but the net loss attributable to common stockholders improved significantly to $1,053,252 ($0.34 per share) from $2,446,461 ($0.80 per share), aided by lower interest expense and income from employee retention credits. However, the company still reported an operating loss of $1,564,671 and faces ongoing risks from occupancy declines, tenant insolvency, increased operational costs, and liquidity pressures related to the pandemic.

• ·Sale of Goodwill Hunting LLC on June 18, 2024 eliminated operating leases from balance sheet.
• ·Senior Secured Promissory Notes increased to $1,591,238 at Dec 31, 2025 from $1,025,000.
• ·Fixed-Rate Mortgage Loans: $24,258,870 at Dec 31, 2025 vs $25,152,756.
• ·Two loans refinanced in Feb 2026 totaling approx. $5.2M with maturity Feb 17, 2027; facilities sold Jan 2026 repaying $5,772,098 principal.
• ·Mortgage at Southern Hills Campus refinanced for 35 years at 2.38% maturing Oct 1, 2056.

15-04-2026

Principal customer sales for the year ended December 31, 2025 showed mixed performance compared to 2024, with Company A increasing to $8,817,331 (+9.5%) and $6,652,611 (+23.7%) across segments, but Company B declining to $6,169,277 (-25.1%) and $980,638 (-47.5%), Company C to $3,068,991 (-31.7%), Company D to $170,148 (-85.7%), offset by new sales from Company E at $1,866,972. Sales of EWCP and TPA products decreased due to lower customer orders, while R&D services increased from a successful project; gross profit as a percentage of sales declined due to increased scaling costs. Cash provided by operating activities decreased to $3,782,193 from $5,568,346 (-32.0%), though bolstered by $3,750,000 proceeds from the sale of the 317 Mendota building.

• ·Gain on sale of property increased due to sale of 317 Mendota building in 2025.
• ·Loss on write-down of property held for sale increased in 2025 when property put up for sale below holding value.
• ·Income from investments decreased due to sale of 30.1% of Florida based LLC in 2024.
• ·Impairment of investment in Lygos recorded in 2025.
• ·Professional fees, R&D, and SG&A expenses increased due to growth, new leases, Panama location, and new product development.
• ·Audited by Assure CPA, LLC (PCAOB ID NO: 444).

15-04-2026

Hall Chadwick Acquisition Corp's 10-K filing details compensation to sponsor Hall Chadwick Capital LLC, including 7,883,293 Class B Ordinary Shares for $25,000 and 407,000 Private Placement Units for $4,070,000, along with ongoing $20,000 monthly administrative support and potential loans up to $300,000 and $2,500,000. Founder shares held by the sponsor and individuals including Alex Bono, Peter Beckhouse, Aaron Dominish, Gregory Woszczalski, Chris Dirckze, and Matthew Hudson are subject to lock-up restrictions until 180 days post-initial business combination or earlier if Class A shares exceed $12.00 for 20 trading days within a 30-day period starting 150 days after. The filing includes audited financial statements and standard risk disclosures on post-acquisition debt impacts, with no operational performance metrics as the company remains pre-business combination.

• ·Anti-dilution protection for sponsor and Class B holders upon conversion to Class A shares at greater than one-to-one ratio.
• ·Potential consulting, success, or finder fees to sponsor, officers, directors, advisors, or affiliates from funds outside trust account.
• ·Transfer restrictions on founder shares include exceptions for affiliates, family gifts, estate distributions, and pro rata sponsor distributions.
• ·Risks include substantial cash flow used for debt principal/interest post-acquisition, limiting dividends, expenses, and acquisitions; borrowing limitations versus less-levered competitors; potential change in control from share issuances affecting NOL carryforwards and management.

15-04-2026

Vivakor, Inc.'s 10-K for the year ended December 31, 2025, shows sharply mixed segment performance: one segment's total revenues plummeted 83.50% YoY to $11,719,760 from $71,028,495, with related party revenues down 73.30%, while another segment's total revenues surged 86.95% to $35,113,592 and a third generated new $57,585,457 in revenues (100% growth from zero). Gross profits improved significantly across segments, rising 44.21% to $7,557,424 in the first, 481.31% to $28,941,924 in the second, and emerging at $45,388 in the third; however, operating cash flow deteriorated to a $15,780,294 use from a $1,810,827 provision in 2024. Long-term contracts, including a 10-year terminal agreement in Colorado City, Texas, and an offtake with Denbury Onshore, LLC (ExxonMobil subsidiary), support recurring revenue visibility.

• ·CEO Mr. Ballengee's $1,000,000 salary paid in common stock shares: 8,286 shares for Oct 2023-Oct 2024 (VWAP $0.6034946), 3,445 shares for Oct 2024-Oct 2025 (VWAP $1.4516084), accruing 3,624 shares for Oct-Dec 2025 (VWAP $0.23), post 1-for-200 reverse stock split.
• ·Related party transactions exceed $120,000 or 1% of average total assets at year-end for last two fiscal years, involving directors, executive officers, or >5% shareholders.
• ·Multiple executive changes in 2025: Ms. Hawley appointed CFO July 24; Mr. Patterson appointed COO August 12; Mr. Nelson resigned CFO July 19; Mr. Shelton resigned COO August 3; Mr. Knapp resigned November 10.

15-04-2026

15-04-2026

Eightco Holdings Inc. reported a sharp revenue decline of 16.76% YoY to $32,981,126 for FY 2025 from $39,621,272 in FY 2024, with gross profit dropping 91.07% to $534,329 amid higher SG&A expenses up 87.27% and a new $33,854,230 impairment charge. The company posted a massive net loss of $262,013,060, driven by a $202,299,922 decline in fair value of digital assets, contrasting with a small net income of $708,527 in 2024; however, total assets surged to $250,193,124 from $50,848,355, bolstered by $175,901,645 in digital assets and $58,501,108 in cash from $448M in financing activities including PIPE and ATM equity raises.

• ·Cash used in operating activities increased to $10,973,526 in FY 2025 from $6,637,101 in FY 2024.
• ·Operating loss widened to $57,214,549 in FY 2025 from $8,192,559 in FY 2024.
• ·Convertible notes payable eliminated in 2025 (zero from $21M total in 2024).
• ·Common shares outstanding increased dramatically to 205,629,592 from 2,479,363 due to PIPE ($251M) and ATM ($187M) issuances.
• ·Non-controlling interest stable at ($414,514).

15-04-2026

SONIM Technologies Inc. reported zero net revenues and zero gross profit for both fiscal years 2025 and 2024, reflecting flat performance with no revenue generation. Operating expenses rose to $5,406 from $3,100, driven by higher general and administrative costs, resulting in a widened net loss of $7,955 compared to $2,883 in 2024. The filing highlights ongoing risks including cryptocurrency volatility, regulatory changes, lack of profitability, and dependence on third-party contractors.

• ·General and administrative expenses: $5,406 in 2025 vs. $3,100 in 2024.
• ·Other income (expense), net: ($902) in 2025 vs. $246 in 2024.
• ·Loss on extinguishment of debt: $161 in 2025 (none in 2024).

15-04-2026

RetinalGenix Technologies Inc. (RTGN) filed its 10-K annual report on April 15, 2026, detailing extensive risk factors across financial, operational, regulatory, and market domains. The company highlights no revenue from commercial sales, ongoing net losses, substantial doubt about its ability to continue as a going concern, dependency on future capital raises that may dilute shareholders, and uncertainties in product development, regulatory approval, manufacturing, and commercialization. Additional risks include product liability, competition, IT dependencies, key personnel retention, stock volatility, and anti-takeover provisions.

15-04-2026

Veea Inc. reported net sales of $222,018 for the year ended December 31, 2025, up 57% from $141,760 in 2024, with gross profit increasing to $152,037 from $58,470 due to a 16% decline in cost of goods sold. Operating expenses fell sharply to $18,987,372 from $84,136,020, driven by significant reductions in product development (-76%), sales and marketing (-57%), general and administrative (-34%), and transaction costs (from $55.0M to $25K), narrowing the net loss to $6,660,038 from $47,547,768 (-86%). However, revenue remains insignificant, losses persist with anticipation of continued significant losses, and there are no plans for cash dividends.

• ·No current plans to pay cash dividends on common stock.
• ·Net cash used in investing activities: $247,337 (2025) vs. $265,445 (2024).
• ·UK R&D Tax Credit: $1,202,554 (2025, -4% YoY).
• ·Depreciation and amortization increased 131% YoY to $632,479.
• ·Company does not currently incur advertising costs.

15-04-2026

Tradewinds Universal reported revenue of $133,222 for the year ended December 31, 2025, down 22% YoY from $171,596 in 2024, while gross profit declined 11% to $133,222 due to zero COGS in 2025 versus $21,645 previously. Operating expenses surged 368% to $1,026,099, driven by $886,105 in consulting and $60,695 in marketing, resulting in a net loss widening to $892,877 from $115,743. However, the company raised equity through share issuances totaling approximately $1.17M (including $894,700 for services and $200,000 for assets), boosting total assets to $307,333 from $31,510 and cash to $16,638 from $210.

• ·New auditor Fruci & Associates II, PLLC (PCAOB #05525) served since 2025.
• ·Intangible assets increased to $216,500 (net) from $31,300, including AI App at $190,000.
• ·No debt or accounts payable; zero current liabilities both years.
• ·Net cash used in operating activities increased to $57,572 from $28,003.
• ·On June 8, 2025, issued 1,500,000 shares for services to a non-affiliated entity.

15-04-2026

15-04-2026

Polar Power, Inc. reported net sales of $6,304 thousand for the year ended December 31, 2025, a 55% decline from $13,970 thousand in 2024, resulting in a gross loss of $3,156 thousand compared to a gross profit of $1,314 thousand the prior year. Operating expenses decreased 7% to $5,267 thousand, driven by reductions in sales and marketing (20%), R&D (16%), and G&A (14%), but the company still posted a larger net loss of $9,133 thousand versus $4,677 thousand in 2024. Cash used in operating activities worsened to $1,061 thousand from $536 thousand, with cash decreasing $298 thousand.

• ·Tier-1 telecommunications customers represented 62% to 91% of aggregated sales over the past five years.
• ·Inventory write-downs increased to $1,967 thousand in 2025 from $900 thousand in 2024.
• ·EPA certification for natural gas DC power generators received in December 2019.
• ·Company performance incentives include targets: Revenue 20-30%, Gross Margin 5-15%, EBITDA 5-15%, Customer Concentration 8-23%, International Sales 7-17%.

15-04-2026

Madison Technologies Inc. (MDEX) reported zero revenue for FY 2025, flat YoY from FY 2024, with net loss expanding 6.4% to $2,980,623 from $2,800,549 amid higher operating expenses (up 65.4% to $499,658). Total liabilities increased 14.2% to $23,441,236, driven by accounts payable (+40.6% to $3,898,315) and interest payable on senior secured notes (+22.9% to $7,866,912), while stockholders’ deficiency worsened to $(23,310,668) from $(20,386,294); total assets remained flat at $130,568. Cash used in operations improved slightly to $330,965 from $394,617, fully offset by a principal shareholder loan.

• ·Professional fees increased to $311,360 in FY 2025 from $248,101 in FY 2024.
• ·Loan from principal shareholder rose to $725,582 as of Dec 31, 2025 from $394,617.
• ·No cash on hand at end of FY 2025 or FY 2024.
• ·Senior secured notes face value $16,500,000 with carrying value flat at $7,340,093.
• ·Valuation allowance fully offsets tax benefit, resulting in $0 income tax expense.

15-04-2026

Creative Realities, Inc. (CREX) filed its 10-K Annual Report on April 15, 2026, detailing extensive risk factors including doubts about the adequacy of funds for future operations, ability to meet debt obligations, going concern status, customer payment issues, and challenges integrating the CDM acquisition with potential failure to achieve synergies. The filing highlights the company's digital signage platforms like ReflectView (scalable to 100,000+ devices), AdLogic (delivering ~50 million ads daily), and others amid a competitive, evolving market and lengthy sales cycles exacerbated by economic downturns. No cash dividends are expected on common stock in the foreseeable future, relying solely on stock appreciation for investor returns.

• ·Risks include material weaknesses in internal controls over financial reporting and reliance on key personnel.
• ·Lengthy sales cycles noted, especially during economic downturns like COVID-19.
• ·Products target digital merchandising, sales assistants, way-finders, kiosks, menu boards, and dynamic signage.

15-04-2026

15-04-2026

Gloo Holdings, Inc. reported total revenue of $94,660 thousand for the year ended January 31, 2026, surging 307.7% YoY from $23,216 thousand, driven by platform revenue growth of 150.1% to $57,208 thousand and platform solutions revenue increase from $330 thousand (N/M). However, operating expenses rose 90.5% to $202,831 thousand, resulting in a wider operating loss of $108,171 thousand (up 29.9% YoY) and net loss of $158,732 thousand (up 85.0% YoY), with Adjusted EBITDA deteriorating to $(74,349) thousand from $(43,305) thousand.

• ·Net cash used in operating activities: $(80,499) thousand in FY2026 vs $(46,134) thousand in FY2025.
• ·Net cash provided by financing activities: $148,971 thousand in FY2026 vs $61,177 thousand in FY2025.
• ·Interest expense increased 202.8% to $14,347 thousand.
• ·Loss from change in fair value of financial instruments: $33,528 thousand in FY2026 (N/M from gain in prior year).

15-04-2026

Omnitek Engineering Corp reported revenues of $1,449,950 for the year ended December 31, 2025, up 42% from $1,019,726 in 2024, with gross margin improving 21% to $552,525, leading to a net income turnaround to $273,639 from a $167,137 loss. However, operating expenses rose 5% to $638,416, resulting in an ongoing operating loss of $85,891 (improved from $148,500), and net cash used in operating activities surged to $244,348 from $30,077 provided. Total assets declined to $754,386 from $1,116,455, with cash dropping sharply to $14,097.

• ·Basic and diluted EPS: $0.01 for 2025 vs ($0.01) for 2024
• ·Inventories net: $296,132 (Dec 31, 2025) vs $267,616 (Dec 31, 2024)
• ·Customer deposits: $388,301 (Dec 31, 2025) down from $845,272 (Dec 31, 2024)
• ·Filing date: April 15, 2026

15-04-2026

Profusa reported zero revenue in 2025, down 100% from $100 thousand in 2024, with net loss surging 288% to $35,823 thousand amid sharply higher operating expenses, including G&A up 732% to $24,902 thousand and R&D up 74% to $2,804 thousand. The company plans near-term commercialization of CE-approved Lumee Oxygen in Europe in early 2026 targeting a 5 million patient TAM for critical limb ischemia, while Lumee Glucose showed promising proof-of-concept data with 11% MARD and zero SAEs, but faces regulatory hurdles and R&D risks. Potential future revenues from data streams aim at a $400 billion market by 2028.

• ·Lumee Oxygen measures dissolved tissue oxygen for up to six months post-injection.
• ·Lumee Glucose demonstrated up to nine months functionality and zero device-related severe adverse events.
• ·Potential future analytes include lactate, CO2, ethanol, pH.

15-04-2026

Arrive AI Inc. reported first-year revenue of $113,250 for 2025, up from $0 in 2024, marking initial commercialization progress. However, total operating expenses increased 129% to $10,465,856, primarily from higher G&A costs, leading to a net loss widening to $12,826,384 from $4,537,901. While R&D expenses declined 21% to $600,510 and sales & marketing fell 14% to $229,206, the company faces substantial doubt as a going concern, material weaknesses in internal controls, and need for additional funding.

• ·Substantial doubt about going concern due to recurring losses and need for additional capital.
• ·Material weaknesses identified in internal control over financial reporting.
• ·Business dependent on IP licensed from CEO; engages in related-party transactions.
• ·Base salaries increased to $2,578,595 in 2025 (+$1,592,946 YoY) due to hiring; one-time success bonuses of $1,866,531.
• ·Public listing in May 2025 contributed to higher legal fees ($185,375) and insurance premiums.

15-04-2026

CERO Therapeutics Holdings, Inc. reported total operating expenses of $18,463,149 for the year ended December 31, 2025, up 14.0% from $16,198,036 in 2024, primarily due to a 46.6% increase in research and development expenses to $10,381,944, although general and administrative expenses declined 11.4% to $8,081,205. The net loss widened to $19,920,262 (139.9% increase from $8,304,423), and net loss attributable to common stockholders surged to $95,526,623 (762.4% increase from $11,089,262) due to deemed dividends exceeding $75 million on various preferred stock series. Net cash used in operating activities rose to $16,080,250 from $12,915,969, leading to a $1,664,680 decrease in cash and cash equivalents compared to a $811,665 increase in 2024.

• ·Gain from settlement of liabilities with vendor was $0 in 2025 vs. $3,339,223 in 2024.
• ·Change in fair value of derivative liabilities and earnout liabilities was $0 in 2025 vs. $5,200,117 gain in 2024.
• ·Share-based inducement expenses of $863,550 and write-off of deferred offering costs of $605,419 in 2025.
• ·Net cash provided by investing activities: $500,000 in 2025 vs. $0 in 2024.
• ·Risks include sufficiency of cash to fund operations and development of product candidates.

15-04-2026

Barfresh Food Group Inc. reported revenue growth of 33% YoY to $14,208,000 in 2025, driven by a new raw and processed milk segment contributing $2,748,000 and 7% growth in frozen beverages and food to $11,460,000. However, gross profit declined 15% YoY to $3,114,000, with frozen beverages gross profit dropping 19% to $2,977,000, resulting in a wider operating loss of $3,432,000 versus $2,773,000 prior year. Total assets surged to $12,830,000 from $3,318,000, boosted by property, plant and equipment at $8,297,000, but current liabilities ballooned to $11,030,000 and net loss was $2,694,000.

• ·Bargain purchase gain of $767,000 in 2025.
• ·Debt guarantee expense of $97,000 in 2025.
• ·Net loss per share improved to $(0.17) from $(0.19).
• ·Cash increased to $325,000 from $235,000.
• ·Line of credit at $1,124,000 as of Dec 31 2025.
• ·Additional paid in capital $67,645,000 as of Dec 31 2025.

15-04-2026

NetBrands Corp. (NBND) reported its first mining revenue of $18,265 in FY2025, up from $0 in FY2024, with gross margin of $9,490 and improved operating loss of $573,557 (down 28% from $798,089), alongside total assets growing to $102,185 from $1,600 driven by mining equipment and cryptocurrency holdings. However, net loss widened 32% YoY to $1,695,935 from $1,285,306 due to $388,712 loss on debt extinguishment and higher $733,666 interest expense, while operating cash use increased to $336,907 from $182,119 and stockholders' deficit grew slightly to $2,413,239. EPS improved to ($0.02) from ($0.06) on higher share count.

• ·Purchased mining equipment for $87,560 in FY2025.
• ·Proceeds from convertible notes $397,590 and loans payable $37,464 in FY2025.
• ·Mining pool fee of 0.3% applied to bitcoin rewards.
• ·Common stock issued for conversions: 105,735,740 shares.

15-04-2026

Nu-Med Plus, Inc. reported zero revenue for the year ended December 31, 2025, unchanged from 2024, with a net loss of $56,182 versus $68,345 in 2024, reflecting an 18% YoY improvement driven by lower operating expenses ($48,955 vs. $63,331). However, cash declined sharply to $661 from $2,373 (down 72% YoY), total assets fell to $7,911 from $9,373, liabilities rose to $279,189 from $224,469 (up 24% YoY), and stockholders' deficit widened to $(271,278) from $(215,096). Operating activities used $47,979 in cash, offset partially by $46,267 from related-party financing.

• ·Basic and diluted EPS $(0.00) for both 2025 and 2024.
• ·No property and equipment net value ($0) as of Dec 31, 2025 and 2024.
• ·No income tax expense or cash paid for taxes in either year.
• ·Convertible note payable steady at $100,000 both years.

15-04-2026

Splash Beverage Group, Inc. reported net revenues of $73,066 for 2025, a 91% decline from $801,273 in 2024, contributing to a net loss of $25,234,834 versus $23,756,551 prior year amid sharply higher operating expenses and other losses like $5.6M debt extinguishment. However, cash and cash equivalents rose to $281,435 from $13,789, total liabilities fell 24% to $16,266,522 from $21,394,034, stockholders' deficit improved to ($15,300,828) from ($18,634,849), and discontinued operations loss narrowed to $885,563 from $6,147,477. Total assets contracted 65% to $965,694 from $2,759,185, highlighting persistent liquidity strains despite some balance sheet progress.

• ·Gross margin improved to $16,898 from negative $119,797.
• ·Net cash used in operating activities from continuing operations reduced to $4,820,018 from $7,303,145.
• ·Loss per share basic and diluted improved to ($11.97) from ($17.68).
• ·Property and equipment, net $12,926 (down from $22,210).

15-04-2026

KALA BIO, Inc. reported a reduced net loss of $26,980 thousand for the year ended December 31, 2025, compared to $38,511 thousand in 2024, primarily due to lower R&D expenses (-15% YoY), a $4,659 thousand gain on contingent consideration remeasurement, and a $5,793 thousand gain on debt extinguishment. However, general and administrative expenses rose $5,289 thousand (+29% YoY), net cash used in operating activities increased to $31,991 thousand (+9% YoY), and cash and equivalents decreased by $43,624 thousand amid negative financing cash flows. The company has suspended active clinical development of KPI-012 following Phase 2b trial results but continues evaluating resumption opportunities.

• ·Suspended active clinical development of KPI-012 but evaluating opportunities to resume.
• ·Ongoing risk of significant operating losses and negative cash flows; may never achieve profitability.
• ·Impairment of right-of-use assets recorded at $1,411 thousand in 2025.
• ·Contingent payments to third parties in high single digits on certain licensing income.

15-04-2026

Cenntro Inc. reported net revenues of $18,080,161 for the year ended December 31, 2025, down 42% YoY from $31,297,393 in 2024, driven by a 43% drop in vehicle sales to $16,080,343 while spare parts and other sales also declined. Gross profit turned to a loss of $2,316,097 from a profit of $7,608,547, exacerbated by $2,824,436 in inventory write-offs and $1,663,432 in write-downs, leading to a net loss attributable to shareholders of $72,981,773, up 63% from $44,866,813. Operating expenses fell to $30,232,669 from $39,449,817 and net cash used in operations improved to $12,619,516 from $21,362,312, but cash and equivalents dropped to $4,638,328.

• ·Provision for credit losses increased to $4,556,311 in 2025 from $393,873.
• ·Inventory write-off of $2,824,436 and write-down of $1,663,432 in 2025.
• ·Change in fair value of equity securities resulted in $26,604,319 loss in 2025.
• ·Net cash from financing activities $4,897,863 in 2025.

15-04-2026

Bioxytran, Inc. reported a reduced net loss of $2,123,077 for the year ended December 31, 2025, compared to $2,366,681 in 2024, driven by decreases in sales and marketing expenses ($64,500 vs. $336,125) and stock-based compensation ($197,377 vs. $634,025), as well as officer salary forfeitures. However, legal and accounting costs increased to $204,870 from $92,149 due to auditor change, miscellaneous G&A rose slightly to $179,594, and the company conducted multiple private placements issuing over 20 million shares for approximately $1 million total, including dilutive issuances at low prices like $0.025/share. Other income/expenses improved to $280,568 from $156,937, aided by derivative fair value gains and debt forgiveness.

• ·Officers forfeited 50% of salaries in 2025 contributing to payroll decrease.
• ·Stock-based compensation in 2025 included $156,655 to affiliates vs. $349,929 in 2024.
• ·Private placements claimed exemptions under Section 4(a)(2)/Rule 506 Reg D, Rule 3(a)(9), or Rule 701.
• ·Debt forgiveness of $133,867 in 2025; no non-controlling interest loss in 2025 vs. $13,324 in 2024.
• ·Loss per share remained flat at $(0.02) basic and diluted both years.

15-04-2026

FRP Holdings, Inc. reported 2025 revenues of $42,846, up 2.6% from $41,774 in 2024, with total assets growing 0.9% to $735,145 and shareholders' equity rising 1.3% to $428,513. However, operating profit plummeted 40.0% to $7,028, net investment income fell 20.6% to $8,824, and net income attributable to the Company declined 47.8% to $3,330 amid higher total debt of $192,554 (up 7.7%). Multi-year trends show revenues steadily increasing but operating profit volatile, dropping from peaks in 2024 and 2023.

• ·Operating profit declined in every quarter of 2025 vs 2024: Q1 $2,325 vs $2,882; Q2 $1,657 vs $2,820; Q3 $1,363 vs $3,083; Q4 $1,683 vs $2,919.
• ·Equity in loss of joint ventures improved to $(9,105) from $(11,359), a 19.8% reduction in loss magnitude.
• ·Number of employees grew to 25 in 2025 from 19 in 2024.
• ·473,242 securities remaining available for future issuance under equity compensation plans.
• ·Market price per share low in 2025 was $22.33, down from 2024 low of $27.48.

15-04-2026

Horizon Space Acquisition I Corp., a SPAC, reported net income of $203,618 for the year ended December 31, 2025, down 90% YoY from $2,112,351, driven by a 75% drop in interest income to $779,992 amid a 94% plunge in Trust Account investments to $1,179,991 following $22 million in shareholder redemptions that reduced redeemable shares from 1,857,989 to 93,484. Operating costs improved 46% to $576,374, narrowing the operating loss, and net income per redeemable share rose to $0.75 from $0.47. However, total liabilities grew 39% to $6,095,957 with increased related-party loans, and shareholders' deficit widened to $(6,045,378) from $(4,389,004).

• ·Promissory notes increased to $1,970,000 from $1,010,000.
• ·Working capital loan from related party rose to $1,314,003 from $700,000.
• ·Extension loan from related party increased to $190,000 from $70,000.
• ·Up to $3,000,000 of founder/affiliate loans may convert to working capital units at $10.00 per unit.
• ·Cash balance grew to $35,894 from $7,815.

15-04-2026

Citi Trends Inc reported FY2025 net sales of $819,962 thousand, up 8.9% YoY from $753,079 thousand, driven by 9.7% comparable store sales growth versus 3.4% in FY2024, resulting in net income of $5,207 thousand compared to a $43,170 thousand loss. This profit was bolstered by a $10,960 thousand gain on the sale of the Savannah office building and a $482 thousand insurance gain, though income from operations was modest at $3,852 thousand after higher SG&A expenses of $313,171 thousand (up 4.4% YoY). The company ended FY2025 with 590 stores after a net closure of 1 and cash of $66,092 thousand, up from $61,085 thousand.

• ·Asset impairment FY2025: $579 thousand (down from $2,536 thousand in FY2024)
• ·Operating cash flow FY2025: $20,954 thousand (vs negative $3,849 thousand in FY2024)
• ·Capex FY2025: $20,330 thousand purchases of property and equipment
• ·Basic EPS FY2025: $0.65 (vs -$5.19 in FY2024)

15-04-2026

Transcode Therapeutics reported a significantly widened net loss of $34.7 million for the year ended December 31, 2025, compared to $16.8 million in 2024, driven by a 38% increase in R&D expenses to $13.4 million and $8.8 million in acquisition-related transaction costs, resulting in total operating expenses rising 79% to $28.0 million. However, the acquisition of Polynoma added substantial goodwill ($25.7 million) and intangible assets ($114.3 million), boosting total assets to $162.4 million from $7.3 million and turning stockholders' equity positive at $10.3 million from a $2.0 million deficit, with cash rising to $17.8 million fueled by $31.5 million in financing activities. Operating cash use intensified to $19.5 million from $13.3 million.

• ·Net loss per share worsened to ($52.59) from ($1,336.63) due to significant share dilution (weighted average shares 689,713 vs 12,558).
• ·Change in fair value of warrant liability was a $9.3 million expense in 2025 vs $0.9 million in 2024.
• ·Series A Non-Voting Convertible Preferred Stock valued at $141.5 million issued primarily for Polynoma acquisition.

15-04-2026

Greenway Technologies, Inc. reported a widened net loss of $1,957,734 for the year ended December 31, 2025, up 29.34% from $1,513,568 in 2024, driven by surging general and administrative expenses (+294.68% to $2,488,047) and research and development costs (+2,301.67% to $1,205,335), while revenues remained flat at $0. The working capital and stockholders' deficits both increased 8.29% to $14,084,783, amid ongoing cash burn from operations (up 101.18% to $893,689 used). A $648,783 gain on legal settlement provided some offset to a $1,700,000 forfeiture of non-refundable deposits, with interest expense slightly down 0.99%.

• ·Net cash used in operating activities increased 59.89% to $710,289 in 2025 from $444,223 in 2024.
• ·Net cash provided by financing activities rose 49.17% to $691,000 in 2025 from $463,230 in 2024.
• ·No cash used in investing activities in either year.
• ·Convertible debt shares: 0 in 2025 vs 4,440,425 in 2024.

15-04-2026

Starfighters Space, Inc. strengthened its balance sheet with total assets rising to $28,386,884 from $10,300,586, fueled by $26,052,150 in financing activities including Reg A financing, IPO proceeds of $22,061,857, and debt conversions, flipping stockholders' equity to a positive $24,900,552 from a $5,890,456 deficit. However, the net loss more than doubled to $16,543,616 from $7,908,777, driven by operating expenses surging 256% to $15,333,932 amid sharp increases in consulting fees (+327% to $4,263,195), professional fees (+221% to $2,521,680), and new R&D spend of $1,027,203. Cash and restricted cash declined to $4,631,720 from $7,100,699, with operating cash burn worsening to $8,227,372 from $3,864,714 and investing outflows at $20,293,757.

• ·Cashless exercise of warrants issued 11,676,166 shares.
• ·Stock-based compensation expense of $6,069,560.
• ·Rick Svetkoff resigned on February 19, 2026.
• ·Short-term investments increased to $15,274,175 from $1,006,517.
• ·Related party notes payable $1,526,126 as of Dec 31 2025.

15-04-2026

Northwest Biotherapeutics' total assets grew to $81,290 from $26,728 YoY, driven by the Advent acquisition adding $35,432 in equity contribution and boosting intangible assets to $53,188 from $1,292. Net loss improved to $60,162 (28% narrower) from $83,778 with R&D expenses down 17.5% to $28,785 and operating cash burn reduced to $44,763 from $57,017; however, revenues were essentially flat at $1,378 versus $1,382 while liabilities rose to $128,860 from $105,708 and stockholders' deficit remained negative at $60,280.

• ·Common stock outstanding as of Dec 31, 2025: 1,555.4 million shares.
• ·Weighted average shares for EPS: 1,456,663 thousand in 2025 vs. 1,242,237 thousand in 2024.
• ·Basic and diluted net loss per share: $(0.04) in 2025 vs. $(0.07) in 2024.
• ·Series C Convertible Preferred Stock liquidation preference: $11.0 million as of Dec 31, 2025.

15-04-2026

Western Uranium & Vanadium Corp. reported revenues of $425,448 for the year ended December 31, 2025, a 131.5% increase YoY from $183,803, driven by operational progress, while total operating expenses declined 26.7% to $7,711,372 from $10,518,580, narrowing the net loss to $7,175,923 ($0.11 per share) from $10,112,037 ($0.18 per share). Cash and equivalents remained stable at $5,620,630 (up slightly from $5,482,631), supported by $7.1M in financing proceeds, though the company continues to report operating losses and cash burn from operations at $5.8M. Total assets grew modestly to $34,446,941 from $33,916,238, with shareholders' equity at $30,302,115.

• ·Mining expenditures declined to $4,447,119 from $5,285,140 YoY.
• ·General and administrative expenses fell to $2,283,333 from $3,599,460 YoY.
• ·Net cash used in operating activities improved to $5,775,735 from $8,297,043 YoY.
• ·Private placements raised $3,331,687 in June 2025 and $3,806,270 in October 2025.
• ·71,853,888 common shares outstanding as of April 14, 2026.

15-04-2026

Constellation Acquisition Corp I reported a widened net loss of $3,239,103 for the year ended December 31, 2025, compared to $248,243 in 2024, driven by a $2,275,191 negative change in warrant liabilities and reduced interest income, though general and administrative costs decreased 32% to $1,068,743. Cash in the Trust Account plummeted 97% to $859,443 from $28,123,011 due to heavy redemptions of 2,303,382 Class A ordinary shares, increasing total liabilities to $23,303,004 and deepening shareholders' deficit to $(23,261,238). While cash used in operating activities improved slightly to $(470,238), related party debt rose with promissory notes at $2,122,109.

• ·Warrant liabilities increased to $2,527,991 from $252,800.
• ·Accounts payable and accrued expenses rose to $4,261,904 from $3,802,862.
• ·Cash withdrawn from Trust Account in connection with redemptions: $27,428,399 in 2025 vs. $23,671,533 in 2024.
• ·Proceeds from promissory notes to related party: $529,901 in 2025.

15-04-2026

For the year ended December 31, 2025, CFN Enterprises Inc. reported net revenues from continuing operations of $36,297, down 89% YoY from $321,352, with gross profit declining 88% to $35,945. While selling, general, and administrative expenses decreased 23% to $1,748,162 and loss from operations improved 13% to $(1,712,217), total net loss including discontinued operations widened to $(6,815,238) from $(4,529,362). Total assets shrank to $1,230,330 from $8,672,137, with cash falling to $197,951, and stockholders' deficit grew to $(23,707,939).

• ·Net loss from discontinued operations: $(4,716,689) in 2025 vs $(2,431,132) in 2024.
• ·Accounts receivable, net: $0 as of Dec 31, 2025 vs $1,525,937 as of Dec 31, 2024.
• ·Inventories, net: $516,124 as of Dec 31, 2025 vs $3,376,189 as of Dec 31, 2024.
• ·Net cash used in investing activities: $(233,544) in 2025 vs $(57,039) in 2024.
• ·Issuance of 300,000 common shares pursuant to asset acquisition valued at $757,500.
• ·Conversion of accrued interest into 60,000 common shares valued at $120,000.

15-04-2026

Sotherly Hotels LP reported total revenue of $176,387,228 for the year ended December 31, 2025, down 3.0% YoY from $181,894,287, with rooms revenue declining to $114,400,434 from $119,079,903 while food and beverage remained relatively flat at $36,458,606. Net operating income fell sharply 38.5% YoY to $12,696,273 from $20,647,862, driven by higher interest expense of $24,799,871 (up 18.8%), resulting in a net loss of $7,779,133 versus net income of $1,179,854 in 2024; Adjusted FFO decreased to $4,873,022 from $14,290,221. Total assets declined to $407,913,819 from $414,375,920, with equity dropping to $28,260,815 from $41,598,766 amid ongoing preferred distributions.

• ·Mortgage loans, net decreased slightly to $315,199,862 from $316,516,148.
• ·Cash flows from operating activities $10,315,065 in 2025, down from $25,889,146 in 2024.
• ·Impairment of investment in hotel properties held for sale: $1,310,308 in 2025.
• ·Preferred stock liquidation preferences increased: Series B to $45,387,100, Series C to $41,603,220, Series D to $36,274,181 as of Dec 31, 2025.

15-04-2026

Drugs Made In America Acquisition II Corp., a SPAC, completed its IPO in 2025, funding the Trust Account to $504,933,800 and generating net income of $4,187,050 for the year ended December 31, 2025, primarily from $4,933,800 in interest income and a $553,748 gain on extinguishment of over-allotment option liability. However, operating expenses increased to $488,385 from $151,719 in the 2024 stub period, a $812,113 provision for credit losses was recorded on sponsor receivables, shareholders' deficit ballooned to $17,774,827 due to $43,561,804 in accretion and remeasurement charges, and cash declined sharply to $223. Total assets reached $504,959,837 as of December 31, 2025, supported by 50,000,000 redeemable shares.

• ·Promissory note – related party fully repaid in 2025 ($250,100 outstanding at Dec 31, 2024).
• ·Forfeiture of 1,875,000 founder shares in 2025.
• ·Basic net income per redeemable ordinary share $0.16 and per non-redeemable $0.16 for 2025.
• ·Deferred offering costs cleared to $0 from $78,449.

15-04-2026

XMax Inc. reported FY2025 net sales of $16,722,703, up 72.7% YoY from $9,686,975, with total assets expanding to $35,547,329 from $9,917,403 driven by a $23,104,628 investment in a fund and $29,752,352 in financing inflows. However, gross profit declined slightly to $4,184,498 (25% margin) from $4,249,491 (44% margin), operating expenses fell but the company incurred a net loss of $3,418,578 (improved from $5,561,705), and cash burn from operations continued at $445,838 amid warnings of needing additional capital. Balance sheet strengthened with stockholders' equity at $27,959,568 versus $3,123,514.

• ·EPS basic and diluted: ($0.17) FY2025 vs ($1.48) FY2024
• ·Weighted average shares outstanding: 20,684,692 FY2025 vs 3,765,727 FY2024
• ·Convertible notes noncurrent liabilities: $5,038,026 as of Dec 31 2025 (new)
• ·Goodwill impairment loss: $218,606 FY2025
• ·Plant, property and equipment written off: $192,726 FY2025

15-04-2026

Eline Entertainment Group, Inc. (EEGI) reported zero revenues for both years ended December 31, 2025 and 2024, with net losses widening to $44,992 in 2025 from $32,877 in 2024 (37% YoY increase in loss magnitude). Operating expenses rose 26% YoY to $44,992, driven by a 768% surge in other G&A expenses to $12,492 despite a slight 4% decline in professional fees to $32,500; total liabilities grew 50% to $134,301, primarily due to increased related party payables. Cash remained at zero, with operating cash burn increasing 32% to $49,191, fully funded by related party advances.

• ·Total assets and cash balances remained at $0 as of Dec 31, 2025 and 2024.
• ·Stockholders’ deficit increased to $(134,301) as of Dec 31, 2025 from $(89,309) as of Dec 31, 2024.
• ·No depreciation/amortization, investing activities, income taxes paid, or interest paid in either year.
• ·Audited by Beckles & Co. Inc. (PCAOB ID: 7116).

15-04-2026

Healthcare Triangle, Inc. (HCTI) reported revenue growth of 19% YoY to $13,891 thousand for the year ended December 31, 2025, from $11,696 thousand in 2024, driven by increases from top customers like Customer 1 (+40% to $2,718 thousand, 20% of revenue) and Customer 2 (+34% to $2,568 thousand, 18% of revenue). However, the net loss widened significantly to $9,476 thousand (-68% of sales) from $5,969 thousand (-51% of sales), due to cost of revenue rising to 86% of sales ($12,001 thousand) from 75% ($8,806 thousand) and general and administrative expenses surging to $7,337 thousand (53% of sales) from $3,950 thousand (34%). Customer concentration remains a risk, with top five customers accounting for 58% of 2025 revenue, including declines for Customer 4 (-3% to $852 thousand) and Customer 5 (-35% to $548 thousand).

• ·Sales and marketing expenses increased to $3,084 thousand (22% of sales) from $2,203 thousand (19%) YoY.
• ·Depreciation and amortization decreased to $705 thousand (5%) from $889 thousand (8%).
• ·Top five customers represented 58% of 2025 revenue vs. 58% in 2024 (Customer 3 flat at ~10-11%).
• ·Weighted average exercise price of outstanding options: $1,093.

15-04-2026

AIBOTICS, INC. reported its first revenue of $2,183 for the year ended December 31, 2025, up from $0 in 2024, marking initial commercialization; however, net loss widened to $2,215,751 from $1,848,275 due to higher operating expenses of $1,846,856 (up from $1,634,817) and additional loss on extinguishment of $144,176. Cash position improved to $255,940 from $185,097 with a net cash increase of $70,843 versus a $94,037 decrease prior year, driven by stronger financing inflows of $529,000, though operating cash use deteriorated to $(458,240) from $(259,037). Total assets declined to $874,673 from $1,456,995, with stockholders' deficit deepening to $(3,960,232).

• ·Company classified as smaller reporting company and non-accelerated filer.
• ·Intangible assets declined to $604,566 from $1,271,888.
• ·EPS improved to $(0.01) from $(0.14) basic and diluted.
• ·Bonus structure: $100,000 for each $1,000,000 EBITDA milestone, up to five.
• ·Average shares outstanding: 186,286,180 in 2025 vs 13,382,703 in 2024.

15-04-2026

CITRINE GLOBAL, CORP. reported a reduced net loss of $1.917M for the year ended December 31, 2025, compared to $2.298M in 2024, primarily due to lower financing expenses. However, total assets declined 25% to $1.211M from $1.620M, driven by a 46% drop in investments, while total liabilities rose 27% to $5.468M and shareholders' deficit widened to $(4.257M) from $(2.695M). Operating loss slightly increased to $1.255M from $1.238M, and cash used in operations surged to $0.464M from $0.004M.

• ·No revenue reported in either year; company remains pre-revenue with ongoing losses.
• ·Loss per common stock basic and diluted: (0.00) for both 2025 and 2024.
• ·Basic weighted average shares outstanding: 1,139,390,134 (2025) vs 1,032,922,840 (2024).

15-04-2026

Cosmos Health Inc. reported growth in select areas, including a 15% YoY increase in wholesale revenues at Cosmofarm S.A., pharmaceutical manufacturing revenues at CANA S.A. nearly doubling from $865,000 to $1.7 million, and UK subsidiary Decahedron Ltd. revenues rising from $815,000 to $2.6 million in 2025. However, the company posted a wider net loss of $19,144,998 compared to $16,183,018 in 2024, driven by high provisions for doubtful accounts of $5,882,393, increased G&A expenses like $2.0 million in management bonuses and $2,312,241 in stock-based compensation, and impairments of $162,785. Total inventory stood at $5,778,142 as of December 31, 2025, with pharmaceuticals comprising 74.73%.

• ·Provisions include $1,400,020 against Montreal land/building advances and $533,288 on other receivables.
• ·Impairments: $90,450 on Cosmofarm e-commerce platform and $72,335 on pharmaceutical licenses.
• ·ATW facility allows up to $300 million, with $292 million available post-initial $8 million draw.
• ·New S-3 registers up to $200,000,000 of securities.
• ·Accounts receivable increase caused $4,939,952 cash outflow.

15-04-2026

Hyperscale Data, Inc. reported total revenue of $102,112,000 for the year ended December 31, 2025, down 4.3% YoY from $106,662,000, with declines in crane operations (-4.2% to $45,459,000) and crypto assets mining (-30.4% to $21,307,000), partially offset by growth in hotel and real estate operations (+7.1% to $20,235,000) and other revenue (+71.4% to $13,383,000). Gross profit fell 10.9% to $21,573,000 from $24,217,000, operating loss widened to $62,268,000 from $56,974,000, and net loss attributable to common stockholders increased 22.1% to $75,039,000 from $61,481,000. RF Solutions (Microphase) maintains a substantial backlog of $31 million as of December 31, 2025.

• ·Microphase recognized as BAE Systems Silver Supplier for 2024 and 2025.
• ·RF Solutions backlog of $31 million as of December 31, 2025, with definite delivery dates for long life cycle platforms.
• ·Depreciation, utilities and other costs, and hosting fees totaled $122,266 in 2025 (up from $68,669 in 2024).
• ·Risks include debt obligations for Circle 8 reducing cash flow availability, potential climate regulation impacts on Circle 8 revenues, and volatility in precious metals prices.

15-04-2026

urban-gro, Inc. reported total revenues of $17,399,438 for FY2025, a 44% YoY decline from $31,203,300, driven by sharp drops in equipment (-29%) and construction design-build (-55%) segments. While gross profit improved to $174,554 from a $388,731 loss and operating expenses fell 35% to $18,186,630, the company posted a net loss of $22,099,032 (narrowed from $36,495,826) amid impairments, write-offs, and a $2.47M loss on assets foreclosure. Balance sheet deteriorated with cash at $10,644 (down 99%), total assets at $331,947 (down 98%), and stockholders' deficit widening to $45,165,234.

• ·Bad debt expense of $1,130,760 and contract receivables write-off of $4,034,280 in FY2025.
• ·Net cash provided by operating activities improved to $840,796 from $(2,821,187) YoY.
• ·Accounts payable rose to $18,202,851 (up 35%) and accrued expenses to $5,708,526 (up 42%).
• ·Related party revenues $0 in FY2025 vs $120,571 in FY2024.
• ·Net loss per share improved to $(41.83) from $(73.12).

15-04-2026

Oncotelic Therapeutics reported a dramatic turnaround with net income attributable to the company of $249,279,832 in 2025 versus a $4,523,932 loss in 2024, driven by a $365,346,775 positive change in fair value of its investment in GMP Bio, which surged to $388,000,000 from $22,653,225, boosting total assets to $393,088,242 from $26,677,426. However, the company continued to post an operating loss of $3,186,599 (improved from $3,576,013), with general and administrative expenses rising sharply to $3,182,242 from $376,013, cash remaining low at $88,857, and working capital negative at ($16,945,000). Stockholders' equity expanded to $261,731,559 from $7,477,512 amid low liquidity and net cash used in operations of $1,383,000.

• ·Net cash used in operating activities increased to $1,383,000 in 2025 from $740,000 in 2024.
• ·Net cash provided by financing activities was $1,386,000 in 2025 versus $656,000 in 2024.
• ·Basic and diluted EPS improved to $0.59 in 2025 from ($0.01) in 2024.
• ·Deferred income tax provision of $111,550,000 in 2025.

15-04-2026

SPINDLETOP OIL & GAS CO's total assets remained stable at $27,451,000 as of December 31, 2025, down slightly from $27,574,000 in 2024, driven by a sharp decline in cash and cash equivalents to $3,641,000 from $6,472,000, offset by growth in other long-term investments to $17,590,000 from $16,575,000. Natural gas production rose 10.8% YoY to 597,299 Mcf with average prices increasing to $3.22/Mcf from $2.44/Mcf; however, crude oil and condensate production declined 3.1% to 27,445 Bbl with prices falling to $62.99/Bbl from $74.13/Bbl, and average production costs per equivalent barrel increased to $22.35 from $20.94. Shareholders' equity decreased to $14,328,000 from $16,561,000, reflecting lower retained earnings of $15,578,000 versus $17,460,000.

• ·Property and Equipment net increased to $1,711,000 from $963,000.
• ·Real Estate Property net declined to $1,242,000 from $1,309,000.
• ·Asset retirement obligation rose to $5,883,000 from $4,314,000.
• ·Treasury stock at cost increased to $(2,270,000) from $(1,919,000).
• ·Auditor: Farmer, Fuqua & Huff, P.C.